Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned a consensus rating of "Buy" from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is $9.57.
A number of equities research analysts have issued reports on the stock. Royal Bank of Canada reissued an "outperform" rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Thursday, September 19th. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a report on Thursday, August 8th. They issued a "buy" rating and a $10.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Friday, August 16th. Finally, Stephens assumed coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They issued an "overweight" rating and a $13.00 price target on the stock.
Check Out Our Latest Report on PYXS
Pyxis Oncology Stock Performance
PYXS stock traded down $0.01 during midday trading on Monday, reaching $4.18. 159,764 shares of the company's stock traded hands, compared to its average volume of 631,845. The company has a 50-day moving average price of $3.69 and a two-hundred day moving average price of $3.65. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a market capitalization of $248.58 million, a PE ratio of -4.07 and a beta of 1.27.
Institutional Investors Weigh In On Pyxis Oncology
Institutional investors have recently made changes to their positions in the company. Fullcircle Wealth LLC purchased a new stake in Pyxis Oncology in the second quarter worth approximately $40,000. Intech Investment Management LLC purchased a new stake in Pyxis Oncology in the third quarter worth approximately $55,000. SG Americas Securities LLC purchased a new stake in Pyxis Oncology in the third quarter worth approximately $58,000. The Manufacturers Life Insurance Company purchased a new stake in Pyxis Oncology in the second quarter worth approximately $65,000. Finally, MetLife Investment Management LLC boosted its holdings in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company's stock worth $69,000 after purchasing an additional 5,484 shares during the last quarter. Hedge funds and other institutional investors own 39.09% of the company's stock.
About Pyxis Oncology
(
Get Free ReportPyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Featured Articles
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
